Press Releases PharmaEssentia Corporation

Equities

6446

TW0006446008

End-of-day quote Taiwan S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
408.5 ^TWD	+5.28%		+30.72%	+18.06%

May. 13	PharmaEssentia Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 26	PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PharmaEssentia - ANALYSES FIND PATIENTS WITH POLYCYTHEMIA VERA TREATED WITH BESREMI HAD INCREASED PROBABILITY OF ACHIEVING COMPLETE HEMATOLOGIC RESPONSE	Apr. 02	AQ
Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role of ropeginterferon alfa-2b-njft	Nov. 02	BU
PharmaEssentia Enters Into Exclusive Global License Agreement With WuXi Biologics for a Myeloid Immune Checkpoint Antibody Candidate	23-10-03	BU
PharmaEssentia Included in FTSE Russell Indices	23-09-18	BU
PHARMAESSENTIA AND MPN ADVOCACY AND EDUCATION INTERNATIONAL LAUNCH NEW EDUCATIONAL INITIATIVE TO EMPOWER PEOPLE LIVING WITH POLYCYTHEMIA VERA	23-09-15	AQ
New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera	23-08-04	BU
New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May Achieve Greater and Quicker Complete Hematologic and Molecular Responses in Polycythemia Vera	23-06-30	BU
PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin America	23-06-02	BU
NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera	23-05-23	BU
PharmaEssentia Initiates Phase 3b Trial of Ropeginterferon alfa-2b-njft Investigatng New Dosing Regimen for Patients With Polycythemia Vera (PV)	23-05-03	BU
PharmaEssentia Corporation Announces Closing of Global Depositary Receipt Offering, Generating US$462.7M to Support Growth Plans and Pipeline Development	23-04-21	BU
PharmaEssentia Initiates Phase 2b Trial of ropeginterferon alfa-2b-njft for Essential Thrombocythemia (ET) in North America	23-02-23	BU
Clinical Review of ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outcomes in Polycythemia Vera	23-02-02	BU
PharmaEssentia Establishes a New Research and Development Facility in the Boston Area	23-01-04	BU
PharmaEssentia to Present at the 41st Annual J.P. Morgan Healthcare Conference	23-01-03	BU
New Ropeginterferon alfa-2b Data Show Importance of Proactive Care Earlier in the Polycythemia Vera Patient Journey	22-12-12	BU
Pharmaessentia to Host Investor Day in New York City on November 30, 2022	22-11-21	BU
Presentations on Ropeginterferon Alfa-2b During ASH Annual Meeting Highlight Momentum in the Care of Polycythemia Vera	22-11-03	BU
PharmaEssentia USA Expands Leadership With Executive Hires in Marketing, Medical Affairs and Communications and Advocacy	22-10-20	BU
Hepatitis C Virus Infection Pipeline Landscape Analysis of 20+ Companies by DelveInsight	22-10-12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases PharmaEssentia Corporation

Equities

6446

TW0006446008

Press Releases

Filters